Page results
-
In a major study involving UCLH a third of people who took a new drug for treating obesity lost more than one-fifth of their total body weight.
-
The world’s first COVID-19 vaccine study researching alternating doses and intervals of approved vaccines is taking place at UCLH.
-
UCLH has recruited the first European participant to a trial looking at treating non-hospitalised Covid-19 patients with the drug remdesivir.
-
This page provides information about the WEB device and how it is used to treat cerebral (brain) aneurysms
-
Our outpatient clinics will remain predominantly virtual throughout the COVID-19 pandemic. Please continue to refer via the NHS e-referral service.
-
All GPs are now welcome to use our national Infectious & Tropical Disease Advice and Guidance function on the e-referral system (NHS e-RS)
-
Around 1 in 250 women may experience consciousness during pregnancy-related surgery under general anaesthesia, according to a national study which sheds light on why this occurs.
-
A new NHS vaccination centre at UCL’s Bidborough House, Bidborough Street, WC1H 9BT opened 26 August 2021.
-
An antibody treatment trialled at UCLH cuts the risk of developing symptomatic COVID-19 by 77%.
-
Court of Appeal has ruled in favour of the Tavistock and Portman NHS Trust, which leads the national Gender Identity and Development Service (GIDS).
File results
-
FOI/2022/0169 - Strategic workforce plan for recruitment and retention of Allied Health Professions
-
FOI/2022/0171 - Consultant-led Referral to Treatment (RTT), outpatients and Patient Initiated Follow-up (PIFU)
-
FOI/2022/0172 - Contraceptive pill data
-
FOI/2022/0174 - Clinical systems for bed management, diagnostic reporting, discharge letters, and integration platform systems
-
FOI/2022/0177 - Assessment and treatment unit for mental health and learning disabilities
-
FOI/2022/0186 - Gender neutral toilets at the Trust
-
FOI/2022/0187 - Intra-operative cell salvage procedures
-
FOI/2022/0189 - Drug treatments for Revolade, Nplate, Doptelet, and Tavlesse
-
FOI/2022/0190 - Spend on private healthcare providers for staff
-
FOI/2022/0192 - Drug treatment for Melanoma patients